Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies

Alan Menter; Joel M. Gelfand; Cody Connor; April W. Armstrong; Kelly M. Cordoro; Dawn M.R. Davis; Boni E. Elewski; Kenneth B. Gordon; Alice B. Gottlieb; Daniel H. Kaplan; Arthur Kavanaugh; Matthew Kiselica; Dario Kivelevitch; Neil J. Korman; Daniela Kroshinsky; Mark Lebwohl; Craig L. Leonardi; Jason Lichten; Henry W. Lim; Nehal N. Mehta; Amy S. Paller; Sylvia L. Parra; Arun L. Pathy; Elizabeth Farley Prater; Robert S. Rahimi; Reena N. Rupani; Michael Siegel; Benjamin Stoff; Bruce E. Strober; Elliot B. Tapper; Emily B. Wong; Jashin J. Wu; Vidhya Hariharan; Craig A. Elmets

doi:10.1016/j.jaad.2020.02.044

Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies

Alan Menter, Joel M. Gelfand, Cody Connor, April W. Armstrong, Kelly M. Cordoro, Dawn M.R. Davis, Boni E. Elewski, Kenneth B. Gordon, Alice B. Gottlieb, Daniel H. Kaplan, Arthur Kavanaugh, Matthew Kiselica, Dario Kivelevitch, Neil J. Korman, Daniela Kroshinsky, Mark Lebwohl, Craig L. Leonardi, Jason Lichten, Henry W. Lim, Nehal N. MehtaAmy S. Paller, Sylvia L. Parra, Arun L. Pathy, Elizabeth Farley Prater, Robert S. Rahimi, Reena N. Rupani, Michael Siegel, Benjamin Stoff, Bruce E. Strober, Elliot B. Tapper, Emily B. Wong, Jashin J. Wu, Vidhya Hariharan^*, Craig A. Elmets

^*Corresponding author for this work

Dermatology

Research output: Contribution to journal › Article › peer-review

209 Scopus citations

Abstract

Psoriasis is a chronic inflammatory disease involving multiple organ systems and affecting approximately 2% of the world's population. In this guideline, we focus the discussion on systemic, nonbiologic medications for the treatment of this disease. We provide detailed discussion of efficacy and safety for the most commonly used medications, including methotrexate, cyclosporine, and acitretin, and provide recommendations to assist prescribers in initiating and managing patients on these treatments. Additionally, we discuss newer therapies, including tofacitinib and apremilast, and briefly touch on a number of other medications, including fumaric acid esters (used outside the United States) and therapies that are no longer widely used for the treatment of psoriasis (ie, hydroxyurea, leflunomide, mycophenolate mofetil, thioguanine, and tacrolimus).

Original language	English (US)
Pages (from-to)	1445-1486
Number of pages	42
Journal	Journal of the American Academy of Dermatology
Volume	82
Issue number	6
DOIs	https://doi.org/10.1016/j.jaad.2020.02.044
State	Published - Jun 2020

Funding

We thank our medical librarian Charniel McDaniels, MS, and our specialist David A. Castillo, BS, for helping with search strings, evidence table generation, as well as with the manuscript publication process. During the development of this guideline, Michael Siegel served as a patient representative for the National Psoriasis Foundation. Funding sources: None. Mark Lebwohl,∗ MD, served as a consultant for Allergan, Almirall, Arcutis, Inc, Boehringer Ingelheim, Bristol-Myers Squibb, Castle Biosciences, Inc, LEO Pharma, Menlo Therapeutics, Mitsubishi Pharma, Neuroderm Ltd, Pfizer, Inc, Promius/Dr. Reddy, Theravance Biopharma, and Verrica Pharmaceuticals Inc receiving honoraria; as a principal investigator or investigator for AbbVie, Amgen, Inc, AstraZeneca, Boehringer Ingelheim, Celgene Corporation, Eli Lilly and Company, Incyte Corporation, Janssen Research and Development LLC/Johnson & Johnson, LEO Pharma, Medimmune, Novartis Pharmaceuticals Corp, Ortho-Dermatologics, Pfizer, Inc, SCIDerm, UCB, and ViDac Pharma receiving grants and/or research funding; and in another role for Corrona, Inc, Facilitation of International Dermatology Education, and the Foundation for Research and Education in Dermatology receiving honoraria. Jashin J. Wu,∗ MD, served as a consultant for AbbVie, Allergan, Almirall, Amgen, Bristol-Myers Squibb, Celgene, Dermira, Dr. Reddy's Laboratories, Eli Lilly and Company, Janssen Biotech, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Inc, Promius Pharma, Regeneron, Sun Pharmaceutical Industries, Ltd, UCB, and Valeant Pharmaceuticals North America, LLC, receiving fees and/or honoraria; as a speaker for AbbVie, Celgene, Novartis, Regeneron, Sanofi Genzyme, Sun Pharmaceutical Industries Ltd, UCB, and Valeant Pharmaceuticals North America, LLC, receiving honoraria; and as a principal/investigator for AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Coherus Biosciences, Dermira, Eli Lilly and Company, Janssen Pharmaceuticals, Inc, Merck & Co, Inc, Novartis, Pfizer, Inc, Regeneron, Sandoz (a Novartis Company), and Sun Pharmaceutical Industries Ltd, receiving research and/or grant funding. Alan Menter,∗ MD, served as a consultant for Abbott Labs, AbbVie, Amgen, Eli Lilly and Company, Galderma USA, Janssen Pharmaceuticals Inc, LEO Pharma US, Menlo Therapeutics, Novartis, Sienna Biopharmaceuticals, and Wyeth Labs receiving honoraria; as a consultant for New Enterprise Associates, Promius Pharma LLC, Spherix Global Insights US, UCB, and Valeant Pharmaceuticals North America receiving fees; as a consultant for Afecta Pharmaceuticals receiving no compensation; as a speaker for Abbott Labs, AbbVie, Amgen, Janssen Biotech, LEO Pharma US, Pfizer, Inc, Promius Pharma LLC, Sienna Pharmaceuticals, UCB, and Wyeth Labs receiving honoraria; as a principal investigator for AbbVie, Amgen, Boehringer Ingelheim, Celgene Corporation, Eli Lilly and Company, Janssen Pharmaceuticals, Inc, Medimetriks Pharmaceuticals, Inc, Merck & Co, Inc, Novartis Pharmaceutical Corp, and Pfizer, Inc, receiving grant and/or research funding; as an investigator for Eli Lilly and Company and UCB receiving honoraria; as an investigator for Abbott Labs, LEO Pharma US, and Sienna Biopharmaceuticals receiving grants; as an advisory board member for Abbott Labs, AbbVie, Boehringer Ingelheim, Eli Lilly and Company, Janssen Pharmaceuticals, Inc, LEO Pharma US, Medscape, Pfizer, Inc, and Sienna Biopharmaceuticals receiving honoraria; as an advisory board member for Amgen receiving grant and/or research funding; as an advisory board member for Afecta Pharmaceuticals receiving no compensation; and as an independent contractor for Prime Education receiving fees.

Keywords

Clinical guidelines for psoriasis
dermatology
nonbiologic systemic
psoriasis
psoriasis guidelines
skin disease

ASJC Scopus subject areas

Dermatology

Access to Document

10.1016/j.jaad.2020.02.044

Cite this

Menter, A., Gelfand, J. M., Connor, C., Armstrong, A. W., Cordoro, K. M., Davis, D. M. R., Elewski, B. E., Gordon, K. B., Gottlieb, A. B., Kaplan, D. H., Kavanaugh, A., Kiselica, M., Kivelevitch, D., Korman, N. J., Kroshinsky, D., Lebwohl, M., Leonardi, C. L., Lichten, J., Lim, H. W., ... Elmets, C. A. (2020). Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. Journal of the American Academy of Dermatology, 82(6), 1445-1486. https://doi.org/10.1016/j.jaad.2020.02.044

@article{80017ede40e04b2b8cceb87a83e93e63,

title = "Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies",

abstract = "Psoriasis is a chronic inflammatory disease involving multiple organ systems and affecting approximately 2% of the world's population. In this guideline, we focus the discussion on systemic, nonbiologic medications for the treatment of this disease. We provide detailed discussion of efficacy and safety for the most commonly used medications, including methotrexate, cyclosporine, and acitretin, and provide recommendations to assist prescribers in initiating and managing patients on these treatments. Additionally, we discuss newer therapies, including tofacitinib and apremilast, and briefly touch on a number of other medications, including fumaric acid esters (used outside the United States) and therapies that are no longer widely used for the treatment of psoriasis (ie, hydroxyurea, leflunomide, mycophenolate mofetil, thioguanine, and tacrolimus).",

keywords = "Clinical guidelines for psoriasis, dermatology, nonbiologic systemic, psoriasis, psoriasis guidelines, skin disease",

author = "Alan Menter and Gelfand, {Joel M.} and Cody Connor and Armstrong, {April W.} and Cordoro, {Kelly M.} and Davis, {Dawn M.R.} and Elewski, {Boni E.} and Gordon, {Kenneth B.} and Gottlieb, {Alice B.} and Kaplan, {Daniel H.} and Arthur Kavanaugh and Matthew Kiselica and Dario Kivelevitch and Korman, {Neil J.} and Daniela Kroshinsky and Mark Lebwohl and Leonardi, {Craig L.} and Jason Lichten and Lim, {Henry W.} and Mehta, {Nehal N.} and Paller, {Amy S.} and Parra, {Sylvia L.} and Pathy, {Arun L.} and Prater, {Elizabeth Farley} and Rahimi, {Robert S.} and Rupani, {Reena N.} and Michael Siegel and Benjamin Stoff and Strober, {Bruce E.} and Tapper, {Elliot B.} and Wong, {Emily B.} and Wu, {Jashin J.} and Vidhya Hariharan and Elmets, {Craig A.}",

note = "Publisher Copyright: {\textcopyright} 2020 American Academy of Dermatology, Inc.",

year = "2020",

month = jun,

doi = "10.1016/j.jaad.2020.02.044",

language = "English (US)",

volume = "82",

pages = "1445--1486",

journal = "Journal of the American Academy of Dermatology",

issn = "0190-9622",

publisher = "Mosby Inc.",

number = "6",

}

Menter, A, Gelfand, JM, Connor, C, Armstrong, AW, Cordoro, KM, Davis, DMR, Elewski, BE, Gordon, KB, Gottlieb, AB, Kaplan, DH, Kavanaugh, A, Kiselica, M, Kivelevitch, D, Korman, NJ, Kroshinsky, D, Lebwohl, M, Leonardi, CL, Lichten, J, Lim, HW, Mehta, NN, Paller, AS, Parra, SL, Pathy, AL, Prater, EF, Rahimi, RS, Rupani, RN, Siegel, M, Stoff, B, Strober, BE, Tapper, EB, Wong, EB, Wu, JJ, Hariharan, V & Elmets, CA 2020, 'Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies', Journal of the American Academy of Dermatology, vol. 82, no. 6, pp. 1445-1486. https://doi.org/10.1016/j.jaad.2020.02.044

Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. / Menter, Alan; Gelfand, Joel M.; Connor, Cody et al.
In: Journal of the American Academy of Dermatology, Vol. 82, No. 6, 06.2020, p. 1445-1486.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies

AU - Menter, Alan

AU - Gelfand, Joel M.

AU - Connor, Cody

AU - Armstrong, April W.

AU - Cordoro, Kelly M.

AU - Davis, Dawn M.R.

AU - Elewski, Boni E.

AU - Gordon, Kenneth B.

AU - Gottlieb, Alice B.

AU - Kaplan, Daniel H.

AU - Kavanaugh, Arthur

AU - Kiselica, Matthew

AU - Kivelevitch, Dario

AU - Korman, Neil J.

AU - Kroshinsky, Daniela

AU - Lebwohl, Mark

AU - Leonardi, Craig L.

AU - Lichten, Jason

AU - Lim, Henry W.

AU - Mehta, Nehal N.

AU - Paller, Amy S.

AU - Parra, Sylvia L.

AU - Pathy, Arun L.

AU - Prater, Elizabeth Farley

AU - Rahimi, Robert S.

AU - Rupani, Reena N.

AU - Siegel, Michael

AU - Stoff, Benjamin

AU - Strober, Bruce E.

AU - Tapper, Elliot B.

AU - Wong, Emily B.

AU - Wu, Jashin J.

AU - Hariharan, Vidhya

AU - Elmets, Craig A.

PY - 2020/6

Y1 - 2020/6

N2 - Psoriasis is a chronic inflammatory disease involving multiple organ systems and affecting approximately 2% of the world's population. In this guideline, we focus the discussion on systemic, nonbiologic medications for the treatment of this disease. We provide detailed discussion of efficacy and safety for the most commonly used medications, including methotrexate, cyclosporine, and acitretin, and provide recommendations to assist prescribers in initiating and managing patients on these treatments. Additionally, we discuss newer therapies, including tofacitinib and apremilast, and briefly touch on a number of other medications, including fumaric acid esters (used outside the United States) and therapies that are no longer widely used for the treatment of psoriasis (ie, hydroxyurea, leflunomide, mycophenolate mofetil, thioguanine, and tacrolimus).

AB - Psoriasis is a chronic inflammatory disease involving multiple organ systems and affecting approximately 2% of the world's population. In this guideline, we focus the discussion on systemic, nonbiologic medications for the treatment of this disease. We provide detailed discussion of efficacy and safety for the most commonly used medications, including methotrexate, cyclosporine, and acitretin, and provide recommendations to assist prescribers in initiating and managing patients on these treatments. Additionally, we discuss newer therapies, including tofacitinib and apremilast, and briefly touch on a number of other medications, including fumaric acid esters (used outside the United States) and therapies that are no longer widely used for the treatment of psoriasis (ie, hydroxyurea, leflunomide, mycophenolate mofetil, thioguanine, and tacrolimus).

KW - Clinical guidelines for psoriasis

KW - dermatology

KW - nonbiologic systemic

KW - psoriasis

KW - psoriasis guidelines

KW - skin disease

UR - http://www.scopus.com/inward/record.url?scp=85083507157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85083507157&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2020.02.044

DO - 10.1016/j.jaad.2020.02.044

M3 - Article

C2 - 32119894

AN - SCOPUS:85083507157

SN - 0190-9622

VL - 82

SP - 1445

EP - 1486

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

IS - 6

ER -

Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies

Abstract

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this